Cactus Life Sciences Top 5 Trends of 2024

Cactus Life Sciences’ Top 5 Trends of 2024: Insights Driving Tomorrow’s MedComms

Here, we revisit our most thought-provoking articles and whitepapers, each addressing pivotal trends that influence the ever-evolving biopharma landscape...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Leverage Social Media to Transform Medical Affairs | Promoting Disease Awareness, Ensuring Compliance and Assessing Outcomes

Leveraging Social Media to Transform Medical

This whitepaper explores the role of social media in...
FINAL Clinical Trial Summaries Blog-Banner-810x540

Clinical Trial Summaries – What Are They and Why Do They Matter for Pharma?

A majority of patients feel lay summaries for clinical trials are very important and won’t...
How Can Preprints Drive Trust In Science?

How Can Preprints Drive Trust in Science?

By tagging preprints with various indicators, badges may represent quality, rigor, and scope. In doing...
equity diversity and inclusion

How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications

A roadmap on how to drive advocacy for EDI in medical communications and publications and...
Medical Affairs - 2025

Vision 2025: Decoding the Medical Affairs Landscape

Medical Affairs is a critical strategic pillars of pharma. Read how Medical Affairs will evolve...
Using digital enhancements to maximize engagement

Using Digital Enhancements to Maximize Engagement: How Are Pharma and Publishers Embracing Digital?

Best practices to implement digital enhancements and measure effectiveness...
Pros and cons of preprints for pharma

Preprints and Pharma: What Works and What Doesn’t

Pharma is cautious of preprints. But should this change? Let’s weigh the pros & cons...

Learn more ABOUT our company.